Virology techniques developed over the past 20 years are routinely used to diagnose and monitor chronic viral infections, such as those caused by hepatitis B virus (HBV) and hepatitis C virus (HCV). Molecular biology tools can be used to detect and quantify viral genomes, sequence them, assign them to a phylogenic clade or subclade (genotype or subtype), and identify clinically relevant nucleotide or amino acid substitutions, such as those associated with resistance to antiviral drugs. Recent advances include real-time target amplification methods for detecting and quantifying viral genomes and next-generation sequencing (NGS) techniques. Other new assays detect and quantify viral antigens, whereas point-of-care tests and alternatives to biologic tests that require whole-blood samples have been developed. We review these methods and how they might be used to diagnose, treat, and manage patients with HBV or HCV infection.
NEW METHODS FOR QUANTIFYING HBV DNA AND HCV RNA
HCV and HBV genomes must be detected and quantified before treatment decisions can be made and to monitor antiviral therapy. The viral genomes can be detected and quantified using target amplification methods, such as the PCR and transcription-mediated amplification (TMA), and with signal amplification methods, such as hybrid-capture and the branched DNA assay. Recently developed real-time target amplification methods have improved viral genome detection and quantification for clinical and research purposes.
Target Amplification Methods
First-generation target amplification techniques have been widely used to diagnose HBV and HCV infections and to monitor responses to antiviral therapies. In Because amplification reactions are saturable, these methods have a narrow dynamic range of quantification. As a result, high levels of virus are not always accurately quantified and require reanalysis after samples are diluted, whereas low levels of virus (such as in patients receiving antiviral therapy) are often not detectable.
This problem was solved by development of real-time target amplification techniques in which quantification takes place during the exponential phase of the amplification reaction. In addition, the reaction is run in a closed system, which prevents carryover contamination and improves specificity.
Real-Time Target Amplification

Real-Time PCR
PCR uses several temperatures and a thermostable DNA polymerase to generate double-stranded DNA amplicons. In assays for HBV, nucleic acids are isolated from a sample and the HBV DNA is directly amplified by PCR. Assays for HCV require reverse probe is linked to a quencher and annealed to the target sequence, between the sense and antisense PCR primers. During each PCR reaction, as the DNA polymerase extends the primer, its intrinsic nuclease activity degrades the probe, releasing the reporter fluorochrome. The amount of fluorescence released during the amplification cycle and detected by the system is proportional to the amount of amplicons generated in each PCR cycle. Software is used to calculate the threshold cycle in each reaction (Ct), which has a linear relationship with the initial amount of nucleic acid. In each PCR run, parallel processing of a panel of quantified standards is used to establish a standard curve for quantification.
Real-Time TMA
The TMA reaction is isothermal and uses 2 enzymes-a reverse transcriptase and a T7 RNA polymerase. The amplicons consist of single-stranded RNA. After lysis of the viral envelope, the viral genome (HBV DNA or HCV RNA) is captured by oligonucleotide probes and bound to magnetic microparticles. Amplification involves autocatalytic isothermal production of RNA transcripts with the 2 enzymes. Each newly synthesized RNA re-enters the TMA process and serves as a template for the next round of replication, resulting in exponential amplification of the target RNA. The amplicons created during amplification are detected in real time, using probes that contain a reporter dye (fluorophore) and a quencher. In the absence of amplicons, these probes exist in a closed configuration, and the fluorescence output of the fluorophore is quenched because it is in close proximity to the quencher. During amplification, when these probes bind to amplicons, the fluorophore and quencher are separated and the fluorescent signal is generated. Software is used to calculate the amount of viral genome in the initial sample by comparison with a panel of quantified standards.
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Available Methods Table 1 shows the performance of current and upcoming commercial real-time PCR and TMA assays. These assays accurately quantify HBV DNA and HCV RNA in clinical practice. [1] [2] [3] [4] [5] The first-generation Cobas Ampliprep ® /Cobas Taqman ® assay substantially underestimated levels of HCV RNA in approximately 30% of patients infected with HCV genotype 4, and occasionally failed even to detect this genotype, due to nucleotide polymorphisms at the hybridization site of the PCR primers or TaqMan probe (in the 5' non-coding region of the HCV genome). 1, 3, 6, 7 This issue has been resolved in the second-generation assay, scheduled for release in 2012. 8 These assays avoid false-positive that result from carryover contamination. They are fully or partly automated (in the latter case, the extract has to be transferred for automated PCR amplification and quantification, after automated extraction). These techniques are recommended to quantify HBV DNA and HCV RNA in international liver society guidelines. [9] [10] [11] [12] [13] [14] 
Future Needs
The advent of real-time PCR and TMA methods has resolved many of the problems of quantifying HBV DNA and HCV RNA in clinical practice. HBV DNA assays need further improvement, to increase their upper limit of quantification-clinicians frequently encounter patients (particularly those that are immunotolerant) with levels of HBV DNA much higher than 10 8 international units (IU)/mL. limit of quantification (LLOQ) defined by the assay manufacturers to assess the ontreatment virologic response and to predict sustained virologic response (SVR). In trials of pegylated IFN-α, ribavirin, and telaprevir or boceprevir, HCV RNA levels below the LLOD (at weeks 4, 8, or 12, depending on the protease inhibitor) were reported to be more predictive of SVR than HCV RNA levels below the LLOQ. 15, 16 However, the LLOQ is, by definition, accurate and reproducible, because it is within the dynamic range of quantification, whereas the LLOD is defined statistically and the actual amount of HCV RNA it indicates varies among patients and samples. Therefore, the LLOD is not suitable for making individual therapeutic decisions. Future assays should have identical LLOD
and LLOQ values, to ensure accurate definition of undetectable levels of HCV RNA. In the meantime, new time points should be defined for accurate assessment using the LLOQ.
NEW SEROLOGIC METHODS
HBsAg Quantification
The level of hepatitis B surface antigen (HBsAg) has been proposed as a marker of infected liver mass or the amount of covalently closed circular DNA, the episomal form of HBV, which persists in hepatocytes. Combined analysis of HBsAg and HBV DNA levels can be used to identify inactive carriers and monitor response to therapy. [17] [18] [19] [20] Two commercial enzyme immunoassays are available; they have narrow dynamic ranges of quantification, so samples that contain high levels of HBsAg must often be retested after 
HCV Core Antigen Detection and Quantification
Levels of HCV core antigen correlate with levels of HCV RNA in patients with chronic HCV infection. [23] [24] [25] [26] Assays that quantify HCV core antigen can therefore be used as alternatives to those that measure levels of HCV RNA, as shown in various populations of patients. 23, [27] [28] [29] The Architect ® HCV Ag assay (Abbott Diagnostics) is commercially available. Its dynamic range of quantification is 3.0-20,000 fmol/L. This assay is CE-marked but has not been approved by the FDA and is available for research use only in the United States. It is less expensive and easier to use than current HCV RNA tests for diagnosis of chronic hepatitis C and monitoring of antiviral therapy. However, the HCV Ag assay's LLOD corresponds to HCV RNA levels of 500-3000 IU/mL, depending on the HCV genotype. 30 Assays for HCV core antigen are therefore not suitable for response-guided therapy, according to current guidelines.
POINT-OF-CARE TESTS AND ALTERNATIVES TO BIOLOGIC TESTS THAT REQUIRE WHOLE-BLOOD SAMPLES
Point-of-care tests are used directly at the site of patient care, outside of the biology laboratory. They include immunoassays based on agglutination, immunochromatography or immunofiltration, as well as assays for nucleic acid detection and quantification. Point-of-care tests can be particularly useful for large-scale screening and improving access to care in regions without molecular biology laboratories.
inserm-00699942, version 1 -22 May 2012
Alternatives to biologic tests that require whole-blood samples, obtained by venipuncture, are being developed. They can use original specimen matrices, such as oral fluids or blood collected from a finger stick into a capillary tube. Blood can be collected on filter paper, known as the dried blood spot (DBS) method, which makes it possible to store desiccated samples for transport as non-hazardous material via regular mail or courier services. DBS collection and storage is easy and, although standard procedures must be carefully followed, little training is required for preparation. HBV DNA and HCV RNA can be detected and quantified from DBS by classic or real-time PCR methods, although at a cost of reduced analytical sensitivity, compared to the whole blood-based methods described above. The reduction in sensitivity results from small input volumes, less-efficient nucleic acid extraction, and nucleic acid degradation in extreme storage conditions. One study reported that the limit of detection of HBV DNA from DBS was approximately 1 Log10 higher than from serum samples. There was a high level of concordance in HBV genotype analysis of DBS and serum samples, and also in detection of precore mutants and drug-resistant variants. 31 In another report, the detection limit for HCV RNA in DBS was about 1000 IU/mL. Concordant results were also obtained from HCV quantification and genotype analyses of serum and DBS. 32 In theory, the analytical sensitivity of viral genome detection from DBS could reach levels similar to those obtained from serum and plasma samples, as recently shown for HIV. 33 Any serum marker, including HBsAg and HCV core antigen, could also be detected and quantified from DBS. However, this has not been tested yet.
NGS
Viral genome sequence analysis can be used to determine HBV or HCV genotype, assess mutations in the HBV core or core promoter, and identify amino acid inserm-00699942, version 1 -22 May 2012 substitutions responsible for resistance to antiviral agents. DNA sequence analysis has been based for many years on the chain termination method, described by Sanger et al. 34 NGS methods offer new opportunities but also create new challenges, because they generate large amounts of data and their results can often be difficult to interpret.
Sequencing Techniques
The Sanger method has been improved by the inclusion of fluorescent labels and capillary electrophoresis. 35, 36 This technique involves DNA denaturation, annealing, and The Sanger sequencing method is well suited for detecting small numbers of substitutions in known genes, but it cannot be used to sequence large portions of plant or animal genomes for genome-wide association studies (GWAS), [37] [38] [39] or to sequence large amounts of targets for gene expression profiling (RNA-Seq). 40 Viruses that establish chronic infections, such as HIV, HBV, and HCV, behave as 
Principles of NGS
NGS methods have been recently developed to increase sequencing capacity while generating clonal sequences. Current NGS methods use a 3-step sequencing process: library preparation, DNA capture and enrichment, and sequencing ( Figure 2 ). 41 In library preparation, DNAs of appropriate lengths are prepared and labeled with the primers required for subsequent isolation and sequencing. DNA is then captured and clonal DNA is enriched (this step is not required with Pacific Biosciences technology).
The DNA is then sequenced, via polymerization combined with detection based on pyrophosphate (pyrosequencing), H+ ions (pH variation) or fluorescence, or ligation combined with fluorescence detection. The detected signals are transformed into readable sequences by an integrated browser and specific software, to produce biologically relevant information. (Table 2) The Illumina technology fragments DNA and then tags the fragments with primers that are complementary to probes, to allow fixation on a flow cell. Clonal DNA is then enriched by PCR, to generate clusters of amplicons, and sequenced, through polymerization with fluorescent dNTPs. 42 The SOLiD system (Applied Biosciences) uses emulsion PCR (emPCR) to enrich clonal DNAs fixed to microbeads. The beads are then transferred to a flow chip and DNA is sequenced by ligation with fluorescent primers. 43 These 2 technologies generate millions of short reads (Table 2) . They are well suited to resequencing when a reference sequence is available (human genome or transcriptome) and the read length of 100-150 bp is sufficient to identify a known gene, for example in GWAS or RNA-seq studies. These technologies can also be used to identify individual substitutions in viral genes, such as those associated with drug resistance. Analysis of a large number of sequences (corresponding to the depth of the reaction) ensures high levels of sensitivity for minor viral variants. However, short reads cannot be used to establish linkages between substitutions located on the same viral variants, which is required for viral resistance studies.
NGS Methods
NGS technologies developed by various manufacturers
The long-read sequencers have more limited sequencing capacities but generate longer sequences. In the GS-based technology, DNA is labeled and clonally enriched by emPCR at the surface of microbeads, which are then loaded in picotiter plates containing over a million wells. During the pyrosequencing reaction, light is emitted every time a new base is inserted by polymerization. 44 The Ion Torrent technology is technically close to the GS technique, but emPCR amplicons are loaded on a semiconductor sequencing inserm-00699942, version 1 -22 May 2012 chip; the addition of nucleotides during the polymerization reaction generates H+ ions, which induce local pH changes that are detected and measured. 45 The PacBio RS technology is substantially different. After preparation of the DNA library, unamplified DNAs are transferred to an optical system, called a zero-mode waveguide, which amplifies fluorescence emitted during polymerization. In this technique, fluorescent signals from each clonal DNA molecule, processed by thousands of polymerase molecules fixed to the zero-mode waveguide, are detected without the need for prior amplification. 46 This group of sequencers generates smaller numbers of sequences, but their length is suitable for linkage studies and de novo characterization of genomic sequences for which no reference sequence is available. They are therefore well suited to virology studies.
Limitations of NGS Methods
All existing methods are susceptible to generating sequencing errors. Evaluations of the Genome Analyzer, 5500 sequencer and GS FLX have calculated accuracy values of 96.7%-100%-similar to those of the classic Sanger method (Table 2) . 47 However, there is controversy about the actual error rates of these methods, so prospective assessments are required by independent investigators. NGS methods generate unreadable sequences (called junk data) at variable rates.
For instance, these rates appear to be high with SOLiD technology on the 5500 sequencer. [47] [48] [49] [50] This is associated with an overcost but not with lower-quality final results, because these sequences can be easily identified and removed. False-positive or false-negative results for substitutions have been reported at higher rates with Illumina technology than the SOLiD and GS FLX technologies. 47, 50 They are easily corrected when inserm-00699942, version 1 -22 May 2012 the sequencing depth is high, as in GWAS or gene expression profiling studies, but are problematic for studies of rare variants.
Performance can be affected by AT-or GC-rich regions, especially with the Illumina and SOLiD technologies, leading to low overall resolution of genome sequences. 51 For the detection of insertions or deletions (indels), the GS-FLX system has been shown to provide the best performance, 47, 52 but it performs less well in homopolymeric regions, where it has high rates of error. 51, 53 
Analyzing NGS Data
In the first step of NGS data analysis, signals generated by the sequencing reaction are converted into readable sequences by proprietary base-caller software. At the end of this step, data are composed of sequences in FASTA format, along with quality scores for each nucleotide of each sequence. The most frequently used format is the PHRED quality score, [54] [55] [56] which is based on base-calling error probabilities.
In the second part of the analysis, the large number of generated sequences must be processed into comprehensible biologic data by software, through 3 steps that depend on the type of study and sample analyzed. 57 The goal of the first step is to classify and format sequences into readable data. In the second step, unreliable sequences are eliminated, including sequences with a Phred quality score below 20 (1% risk of base-caller error) 58 and excessively short sequences (the precise cut-off depends on the technology used). The third step, sequence alignment, is critical and particularly difficult for viral sequences, because of the level of natural genetic variation (numerous to take into consideration the specificities of viral infections. 59-64 Additional alignment quality filters are therefore needed. This part of the analysis must ultimately generate a set of formatted sequences that can be used with confidence for specific analyses and to generate clinically meaningful information.
We recently developed in-house software to model the dynamics of viral populations during and after antiviral therapy and characterize drug resistance. [64] [65] [66] This software package has been used to demonstrate the preexistence of amino acid substitutions that confer HBV and HCV resistance to specific antiviral drugs. It has also been used to characterize the complex dynamics of sensitive and resistant viral populations in patients with chronic hepatitis B treated with adefovir and in patients with chronic hepatitis C treated with telaprevir combined with pegylated IFN-, with or without ribavirin. 64, 65 
Future Needs
The main advantage of NGS techniques for studying chronic viral infections is circumstances. Reading lengths will need to be extended considerably to meet this need (the HBV genome contains approximately 3000 bp, the HCV genome 10,000 bp).
Currently, the main need is for bioinformatic tools to analyze NGS sequences in the context of viral infections. Complex tools might be suitable for research purposes, but clinicians will require bioinformatic tools that can translate millions of generated sequences into simple, clinically relevant information on which therapeutic decisions can be made.
CLINICAL USE OF VIROLOGIC TOOLS
HBV Infection
Tests that are useful for patients with HBV infection include enzyme immunoassays that detect HBV antigen and antibodies, assays that detect and quantify HBV DNA, and methods that identify amino acid substitutions associated with HBV resistance to nucleoside/nucleotide analogues. There is debate over the value of assays that quantify HBsAg. Tools that determine HBV genotype or identify core and core promoter mutants are valuable for research but have no clinical use.
Diagnosis and Prognosis
Chronic HBV carriers are defined by the persistence of HBsAg in their blood for more than 6 months. Chronic hepatitis B is characterized by a level of HBV DNA >2000-20,000 IU/mL (i.e. >3.3-4.3 Log10 IU/mL), a persistent or intermittent increase in level of aminotransferase, and specific features of liver biopsies. 9, 13, 14 Patients with viral loads below 2000 IU/mL are generally considered to be inactive carriers, although there is controversy over this value.
The level of HBV DNA has prognostic value. A chronically high level of HBV DNA
inserm-00699942, version 1 -22 May 2012
is associated with a significant risk of progression to cirrhosis and hepatocellular carcinoma 67, 68 . However, no HBV DNA threshold has been established that has a strong predictive value for the occurrence of clinical outcomes, at the individual level.
Decision to Treat
The decision to treat chronic hepatitis B is based on multiple parameters, including the level of HBV DNA. The European Association for the Study of the Liver Clinical Practice Guidelines state that HBV therapy is indicated for non-cirrhotic patients with an HBV DNA level >2000 IU/mL (>3.3 Log10 IU/mL), serum levels of alanine aminotransferase (ALT) activity above the upper limit of normal (ULN), and a liver biopsy (or a non-invasive test) that indicates moderate to severe activity (METAVIR grade ≥A2) and/or fibrosis (METAVIR stage ≥F2). 9 Patients with compensated cirrhosis and detectable HBV DNA should be considered for treatment and patients with decompensated cirrhosis require urgent antiviral treatment, whatever the level of HBV replication. 9 The Clinical Practice Guidelines of the American Association for the Study of Liver Diseases and the Asian-Pacific Association for the Study of the Liver state that antiviral treatment should be considered for non-cirrhotic patients with HBV DNA titers >20,000 IU/mL (>4.3 Log10 IU/mL) if they are HBeAg positive, or >2000 IU/mL (>3.3 Log10 IU/mL) if they are HBeAg negative, and if they have increased serum levels of ALT activity (>2 x ULN), and/or a liver biopsy showing inflammation and/or fibrosis. 13, 14 Patients should not be tested for drug resistance before therapy.
In patients with normal ALT activity, serum levels of HBV DNA and ALT should be measured at 3-to 6-month intervals. More frequent monitoring should be considered during the first year for hepatitis B e antigen (HBeAg)-negative patients with normal inserm-00699942, version 1 -22 May 2012 levels of ALT and a level of HBV DNA <2000 IU/mL (<3.3 Log10 IU/mL), to confirm their status as inactive carriers.
Choice of Therapy
Pegylated interferon (IFN)- is considered to be the first-line treatment option for HBeAg-positive patients without cirrhosis who have increased levels of ALT and a low level of HBV DNA (<2 x 10 6 IU/mL, such as <6.3 Log10 IU/mL). This treatment is more controversial for HBeAg-negative patients with the same characteristics. 9 The HBV genotype is a significant predictor of the response to pegylated IFN-. However, the individual predictive value of the HBV genotype for the outcome of pegylated IFN- therapy is weak and could be biased by the relationship between genotype and ethnicity. 69, 70 Most patients are treated with nucleoside or nucleotide analogues. The international liver society guidelines recommend either tenofovir or entecavir monotherapy as the first-line treatment for chronic hepatitis B. 9, 13, 14, 71 The HBV genotype has no influence on the effectiveness of nucleoside/nucleotide analogues. 70 
Monitoring Treatment
The ideal endpoint of therapy is a sustained loss of HBsAg, with or without seroconversion to anti-HBs. 9 However, this is rarely achieved with current drugs. The practical aim is therefore to reduce levels of HBV DNA as far as possible (ideally below 10-20 IU/mL), to achieve biochemical remission and histologic improvement and prevent HBV-related liver disease. 9, 13, 14 Treatment of HBeAg-positive patients is therefore monitored by assays for HBV DNA and ALT every 3 to 6 months and HBeAg and anti-HBe every 6 months.
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Treatment of HBeAg-positive patients can be stopped after a consolidation period of 6 to 12 months following HBe seroconversion. 9, 13, 14 However, durable HBe seroconversion, in association with low levels of HBV replication, is rare following treatment with nucleoside/nucleotide analogues. In HBeAg-positive patients who do not develop anti-HBe antibodies, and in HBe-negative patients, nucleoside/nucleotide analogues must be administered for life, with the aim of achieving profound and durable HBV DNA suppression. If HBV DNA is still detectable (>10-20 IU/mL) after 48 weeks of therapy, current guidelines, based on studies of modestly potent nucleoside/nucleotide analogues with low barriers to resistance, recommend adding a second drug with no viral cross-resistance to the first to prevent emergence of resistant variants. However, this is not necessary with entecavir or tenofovir if the HBV DNA level continues to decrease after week 48, because it is likely to become undetectable thereafter. 72 Serial measurements of HBsAg levels could help identify patients who will subsequently clear HBsAg.
In patients who adhere and respond to treatment, selection of resistant HBV variants should be suspected if virologic breakthrough occurs, defined as a re-increase in the HBV DNA level by 1 Log10 or more above the nadir, or as HBV DNA that becomes detectable after being undetectable. 14, 73 A blip (single detection of a low-level of HBV DNA, preceded and followed by undetectable HBV DNA), should not be considered a virologic breakthrough. If resistance occurs, the only effective strategy is to add a second drug against which the selected HBV variant is not cross-resistant. is HBV with the rtA181V/T substitution-it has full sensitivity to only entecavir, which must be combined with tenofovir.
Clinical Research
Cohort studies, surveillance studies, and clinical trials of new therapeutic reagents or strategies require serial measurements of HBV DNA. In research studies, tests for resistant variants should be systematically performed when antiviral therapy fails, to identify the resistant variant and characterize its nature and dynamics. Sensitive sequencing methods such as NGS are particularly useful for characterizing the dynamics of sensitive and resistant virus populations over time. Information about HBV genotype and core and core promoter mutations might be used in epidemiology and pathophysiology studies.
HCV Infection
Assays that detect antibodies against HCV, detect and quantify HCV RNA, or determine HCV genotype are useful for diagnosis and treatment of HCV infection. Assays that detect and quantify HCV core antigen are alternatives to tests for HCV RNA, but are not sensitive enough to use in treatment monitoring or response-guided therapy.
Resistance testing is not useful for patient management but is widely used in clinical trials of DAA or host-targeted agents, in case of treatment failure.
Diagnosis and Decision to Treat
Patients are diagnosed with chronic HCV infection based on the detection of anti-HCV antibodies by enzyme immunoassays and HCV RNA by a sensitive molecular biology-based technique that has a detection limit of about 10 to 15 IU/mL.
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All treatment-naïve patients with compensated liver disease and detectable HCV RNA should be considered for therapy. 10, 12 Assessment of liver disease severity is important for decision making. 10, 12 Patients infected with HCV genotype 1, in whom pegylated IFN-α and ribavirin combination therapy failed to eradicate the virus, should be considered for retreatment, because they might benefit from the triple combination of pegylated IFN-α, ribavirin, and a protease inhibitor.
Selecting Therapy
The HCV genotype should be determined before treatment is started. Patients infected with HCV genotypes other than type 1 should be treated with pegylated IFN-α and ribavirin alone. For patients infected with genotypes 2 or 3, the dose of ribavirin is 0.8 g/day and the treatment duration is 24 weeks; patients with genotypes 2 and 3 with baseline factors that indicate low responsiveness should receive weight-based ribavirin. 10 For patients infected with genotypes 5 and 6, the dose of ribavirin is based on body weight, and treatment should last up to 72 weeks, depending on the virologic response during treatment.
Patients infected with HCV genotype 1 who qualify for therapy should receive the triple combination of pegylated IFN-α, ribavirin, and either telaprevir or boceprevir. The subtype (1a or 1b) does not need to be determined for patients that receive the combination of pegylated IFN-α and ribavirin, or triple drug combinations that include a protease inhibitor, because genotype 1 subtypes do not affect treatment decisions with these therapeutic strategies. 74 Further trials are needed to improve the selection of patients infected with HCV genotype 1 who might not need protease inhibitors, such as young patients with mild fibrosis, a low baseline level of HCV RNA, or the CC IL28B genotype. 75 inserm-00699942, version 1 -22 May 2012
Monitoring Treatment
The endpoint for HCV therapy is a SVR, characterized by undetectable HCV RNA (<10-15 IU/mL) 24 weeks after the end of treatment-this corresponds with viral eradication in more than 99% of cases.
Monitoring of HCV RNA levels during treatment is key in determining virologic response, in guiding duration of treatment, and in deciding futility of treatment. This is particularly important when direct acting antivirals are used, as reviewed by Barritt and Fried in this issue.
Failure of triple combination therapy to clear HCV is associated with outgrowth of variant populations that are resistant to the protease inhibitor used. However, resistance testing based on HCV sequence analysis of the protease region has no utility in clinical practice. 76 Resistant variants are present in almost all infected patients before therapy begins, but technologies available in clinical virology laboratories are not sensitive enough to detect them; 65 negative results are therefore uninterpretable. In addition, the profile of HCV variants at the start of therapy does not appear to affect the outcome of treatment when the protease inhibitor is combined with pegylated IFN-α and ribavirin. At the time of treatment failure (virologic breakthrough or relapse), the resistant population is always enriched, and phase 2 and 3 trials have reported that that it is dominant in 50% to 70% of patients. 77, 78 Resistance testing is still not indicated at this time because the results will have no impact on subsequent treatment decisions. 76 
Clinical Research
In cohort studies, surveillance studies, and clinical trials of HCV DAA or hosttargeting agents, given alone or in combination, serial HCV RNA testing is needed to 
